• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[欧洲血脂异常新指南]

[New european guidelines for dyslipidemia].

作者信息

Riesen Walter F, Virgini Vanessa, Vogt Bruno, Rodondi Nicolas

出版信息

Rev Med Suisse. 2012 Mar 7;8(331):525-6, 528-30.

PMID:22471115
Abstract

Lifestyle changes should be considered before anything else in patients with dyslipidemia according to the new guidelines on dyslipidemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). The guidelines recommend the SCORE system (Systematic Coronary Risk Estimation) to classify cardiovascular risk into four categories (very high, high, medium or low risk) as the basis for treatment decisions. HDL cholesterol, which is inversely proportional to cardiovascular risk, is included to the total risk estimation. In addition to calculating absolute risk, the guidelines contain a table with the relative risk, which could be useful in young patients with a low absolute risk, but high risk compared to individuals of the same age group.

摘要

根据欧洲心脏病学会(ESC)和欧洲动脉粥样硬化学会(EAS)发布的血脂异常新指南,对于血脂异常患者,应首先考虑改变生活方式。这些指南推荐使用SCORE系统(系统性冠状动脉风险评估)将心血管风险分为四类(极高、高、中或低风险),作为治疗决策的依据。高密度脂蛋白胆固醇与心血管风险呈负相关,被纳入总风险评估。除了计算绝对风险外,指南还包含一个相对风险表,这对于绝对风险较低但与同年龄组个体相比风险较高的年轻患者可能有用。

相似文献

1
[New european guidelines for dyslipidemia].[欧洲血脂异常新指南]
Rev Med Suisse. 2012 Mar 7;8(331):525-6, 528-30.
2
Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.法国全科医疗中接受降脂治疗患者的混合性血脂异常:一项观察性研究。
Clin Ther. 2007 Aug;29(8):1671-81. doi: 10.1016/j.clinthera.2007.08.003.
3
Dyslipidemia therapy update: the importance of full lipid profile assessment.血脂异常治疗进展:全面血脂谱评估的重要性
Adv Ther. 2009 Jul;26(7):711-8. doi: 10.1007/s12325-009-0052-3. Epub 2009 Jul 27.
4
New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理新指南——共识背后是否存在争议?
Eur J Cardiovasc Prev Rehabil. 2011 Oct;18(5):724-7. doi: 10.1177/1741826711418946.
5
[New European guidelines for the management of dyslipidaemia in cardiovascular prevention].[欧洲心血管疾病预防中血脂异常管理新指南]
Rev Med Liege. 2012 Mar;67(3):118-27.
6
Cardiovascular risk stratification according to the 2003 ESH-ESC guidelines in uncomplicated patients with essential hypertension: comparison with the 1999 WHO/ISH guidelines criteria.根据2003年欧洲高血压学会(ESH)和欧洲心脏病学会(ESC)指南对单纯原发性高血压患者进行心血管风险分层:与1999年世界卫生组织/国际高血压学会(WHO/ISH)指南标准的比较。
Blood Press. 2004;13(3):144-51. doi: 10.1080/08037050410033169.
7
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).欧洲心脏病学会(ESC)和欧洲动脉粥样硬化学会(EAS)血脂异常管理指南:欧洲心脏病学会(ESC)和欧洲动脉粥样硬化学会(EAS)血脂异常管理特别工作组
Atherosclerosis. 2011 Jul;217 Suppl 1:S1-44. doi: 10.1016/j.atherosclerosis.2011.06.012.
8
[New European clinical guidelines on dyslipidemias].[欧洲血脂异常新临床指南]
Duodecim. 2012;128(16):1651-62.
9
Pathogenesis and management of the dyslipidemia of the metabolic syndrome.代谢综合征血脂异常的发病机制与管理
Metab Syndr Relat Disord. 2009 Apr;7(2):83-8. doi: 10.1089/met.2008.0079.
10
[The new 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk: comparison with the ESC/EAS recommendations for the management of dyslipidemias].[2013年美国心脏病学会/美国心脏协会关于降低动脉粥样硬化性心血管风险的血脂治疗新指南:与欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理建议的比较]
G Ital Cardiol (Rome). 2014 Jan;15(1):19-20. doi: 10.1714/1394.15514.

引用本文的文献

1
Trends and determinants of prevalence, awareness, treatment and control of dyslipidaemia in canton of Geneva, 2005-2019: Potent statins are underused.2005 - 2019年日内瓦州血脂异常患病率、知晓率、治疗率和控制率的趋势及决定因素:强效他汀类药物未得到充分利用。
Int J Cardiol Cardiovasc Risk Prev. 2023 May 19;18:200187. doi: 10.1016/j.ijcrp.2023.200187. eCollection 2023 Sep.
2
Lipid management: maximising reduction of cardiac risk.血脂管理:最大程度降低心脏疾病风险
Clin Med (Lond). 2013 Dec;13(6):618-20. doi: 10.7861/clinmedicine.13-6-618.